The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

“Recurrent or metastatic cervical cancer remains a significant challenge for patients, highlighting a critical unmet need for effective treatments that extend survival after relapse,” said Dr ...

as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The approval means ...

The American Cancer Society's annual cancer trend report shows cancer mortality is decreasing but cancer rates are increasing in young adults and women.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Seagen unit in partnership with Danish biotech Genmab (GMAB), supported Tivdak’s full approval in the U.S. last year for patients with recurrent or metastatic cervical cancer who had undergone ...

Previously, clinical research findings on cadonilimab in the treatment of various malignancies have been published in internationally renowned journals such as The Lancet, The Lancet Oncology, Nature ...

Keytruda is already approved by the FDA as a first-line therapy for PD-L1-positive metastatic cervical cancer in combination with chemo, with or without bevacizumab, and as a second-line therapy ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...